Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 5, 2002, Pages 577-582

  Van Cott, Elizabeth M ^a   Soderberg, Britt L ^a   Laposata, Michael ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; FIBRIN; FIBRINOGEN; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ALGORITHM; ANTICOAGULATION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; GENE MUTATION; HUMAN; LABORATORY TEST; MEDLINE; PUBLICATION; RISK FACTOR; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ALGORITHMS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DNA; FACTOR V; HUMANS; POINT MUTATION; POLYMERASE CHAIN REACTION; THROMBOSIS;

EID: 0036244899     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Laboratory evaluation of hypercoagulable states
2. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V
3. Endothelial cell protein C receptor plays an important role in protein C activation in vivo
4. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
5. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism
6. Anticoagulant protein C pathway defective in majority of thrombophilic patients
7. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study
8. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese
9. Factor V Cambridge: A new mutation (Arg306 → Thr) associated with resistance to activated protein C
10. Factor V Arg 306 → Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese
11. Factor V HR2: An ancient haplotype out of Africa: Reasons for being interested
12. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C
13. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors: Correlation wíth correlation with absence of Arg506-Gln mutation of factor V gene
14. A racial difference in the prevalence of the Arg506→Gln mutation
15. Absence of factor V Leiden in Japanese
16. World distribution of factor V Leiden
17. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening
18. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
19. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
20. Resistance to activated protein C as a basis for venous thrombosis
21. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen
22. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
23. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
24. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation
25. Oral contraceptives and the risk of venous thrombosis
26. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
27. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males
28. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
29. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia
30. The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation
31. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden
32. Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation
33. Factor V Leiden paradox: Risk of deep-vein thrombosis but not of pulmonary embolism
34. Antithrombotic therapy for venous thromboembolic disease
35. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden
36. Activated protein C resistance assay performance: Improvement by sample dilution with factor V-deficient plasma
37. Comparison of an activated partial thromboplastin time with Russell viper venom time test in screening for factor V Leiden (FVRS06Q)
38. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis: Functional tests and DNA-based assays, pros and cons
39. Influence of storage conditions on activated protein C resistance assay
40. Modified test for activated protein C resistance
41. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria
42. Low levels of protein S activity in factor V depleted plasma used in APC resistance test
43. A new dilution for the modified APTT-based assay for activated protein C resistance: Improvement of the reliability in patients with a lupus anticoagulant
44. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract
45. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant
46. Whole blood screening test for factor V Leiden using a Russell viper venom time-based assay
47. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gln mutation
48. Resistance to activated protein C (APCR): Reference values of APC-ratios for children
49. APC resistance in neonates and infants: Adjustment of the APTT-based method
50. Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children
51. Standardization of the APC resistance test: Effects of normalization of results by means of pooled normal plasma
52. Factor V R506Q gene mutation analysis by PCR-RFLP: Optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls
53. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
54. Mutation in blood coagulation factor V associated with resistance to activated protein C
55. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction
56. A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescent resonance energy transfer (FRET) assay
57. Non-PCR-dependent detection of the factor V Leiden mutation from genomic DNA using a homogeneous invader microtiter plate assay
58. Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes
59. How to work up hypercoagulability